CoChat

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models

Open access
Longo, Miriam, Meroni, Marica, Paolini, Erika, Erconi, Veronica, Carli, Fabrizia, Fortunato, Francesco, Ronchi, Dario, Piciotti, Roberto, Sabatini, Silvia, Macchi, Chiara, Alisi, Anna, Miele, Luca, Soardo, Giorgio, Comi, Giacomo Pietro, Valenti, Luca, Ruscica, Massimiliano, Fracanzani, Anna L., Gastaldelli, Amalia, Dongiovanni, Paola · 2022 · Cellular and Molecular Gastroenterology and Hepatology
Cited by 112

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

The co-presence of I148M Patatin-like Phospholipase Domain-containing 3 (PNPLA3), the rs641738 close to Membrane Bound O-acyltransferase Domain-containing 7 (MBOAT7) and the E167K Transmembrane 6 Superfamily Member 2 (TM6SF2) at-risk variants impacts on nonalcoholic fatty liver disease (NAFLD) course, in both patients and experimental models.They affect lipid droplets accumulation, mitochondrial functionality and metabolic reprogramming leading to hepatocarcinogenesis.METHODS: NAFLD patients (n ¼ 1380), of whom 121 had HCC, were stratified with a semiquantitative score ranging from 0 to 3 according to the number of PNPLA3, TM6SF2, and MBOAT7 atrisk variants.TM6SF2 was silenced in HepG2 (TM6SF2 -/-) and MBOAT7 -/-(MBOAT7 -/-TM6SF2 -/-) through Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9). RESULTS:In NAFLD patients, the additive weight of these mutations was associated with liver disease severity and an increased risk of developing HCC.In HepG2 cells, TM6SF2 silencing altered lipid composition and induced the accumulation of microvesicular lipid droplets (LDs), whereas the MBOAT7 -/-TM6SF2 -/-cells showed a mixed microvesicular/ macrovesicular pattern of LDs.TM6SF2 deletion strongly affected endoplasmic reticulum and mitochondria ultrastructures, thus increasing endoplasmic reticulum/oxidative stress.The mitochondrial number was increased in both TM6SF2 -/- and MBOAT7 -/-TM6SF2 -/-models, suggesting an unbalancing in mitochondrial dynamics, and the silencing of both MBOAT7 and TM6SF2 impaired mitochondrial activity with a shift toward anaerobic glycolysis.MBOAT7 -/-TM6SF2 -/-cells also showed the highest proliferation rate.Finally, the re-overexpression of MBOAT7 and/or TM6SF2 reversed the metabolic and tumorigenic features observed in the compound knockout model. CONCLUSIONS:The co-presence of the 3 at-risk variants impacts the NAFLD course in both patients and experimental models, affecting LD accumulation, mitochondrial functionality, and metabolic reprogramming toward HCC. (

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcmgh.2021.11.007

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 35

  1. Day, 2006, From fat to inflammation, Gastroenterology, 130, 207, 10.1053/j.gastro.2005.11.017 · DOI · Paper page
  2. Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI · Paper page
  3. Dongiovanni, 2015, Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis, Biomed Res Int, 2015, 460190, 10.1155/2015/460190 · DOI · Paper page
  4. Meroni, 2021, Genetics is of the essence to face NAFLD, Biomedicines, 9, 1359, 10.3390/biomedicines9101359 · DOI
  5. Mancina, 2016, The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent, Gastroenterology, 150, 1219, 10.1053/j.gastro.2016.01.032 · DOI · Paper page
  6. Meroni, 2020, Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes, EBioMedicine, 52, 102658, 10.1016/j.ebiom.2020.102658 · DOI · Paper page
  7. Donati, 2017, MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals, Sci Rep, 7, 4492, 10.1038/s41598-017-04991-0 · DOI · Paper page
  8. Li, 2017, Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics, Int J Mol Sci, 18, 2550, 10.3390/ijms18122550 · DOI
  9. Xu, 2019, Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China, Ann Hepatol, 18, 456, 10.1016/j.aohep.2018.10.005 · DOI
  10. Krawczyk, 2017, Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study, J Lipid Res, 58, 247, 10.1194/jlr.P067454 · DOI · Paper page
  11. O'Hare, 2017, TM6SF2 rs58542926 impacts lipid processing in liver and small intestine, Hepatology, 65, 1526, 10.1002/hep.29021 · DOI · Paper page
  12. Prill, 2019, The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids, Sci Rep, 9, 11585, 10.1038/s41598-019-47737-w · DOI · Paper page
  13. Tandra, 2011, Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease, J Hepatol, 55, 654, 10.1016/j.jhep.2010.11.021 · DOI · Paper page
  14. Luukkonen, 2017, Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD, J Hepatol, 67, 128, 10.1016/j.jhep.2017.02.014 · DOI
  15. Testerink, 2009, Depletion of phosphatidylcholine affects endoplasmic reticulum morphology and protein traffic at the Golgi complex, J Lipid Res, 50, 2182, 10.1194/jlr.M800660-JLR200 · DOI
  16. Verkade, 1993, Impaired biosynthesis of phosphatidylcholine causes a decrease in the number of very low density lipoprotein particles in the Golgi but not in the endoplasmic reticulum of rat liver, J Biol Chem, 268, 24990, 10.1016/S0021-9258(19)74561-X · DOI · Paper page
  17. Krahmer, 2011, Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase, Cell Metab, 14, 504, 10.1016/j.cmet.2011.07.013 · DOI · Paper page
  18. Kalhan, 2011, Plasma metabolomic profile in nonalcoholic fatty liver disease, Metabolism, 60, 404, 10.1016/j.metabol.2010.03.006 · DOI · Paper page
  19. Li, 2011, A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease, J Proteome Res, 10, 2797, 10.1021/pr200047c · DOI
  20. Beyoğlu, 2013, The metabolomic window into hepatobiliary disease, J Hepatol, 59, 842, 10.1016/j.jhep.2013.05.030 · DOI · Paper page
  21. Min, 2014, Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells, Am J Physiol Gastrointest Liver Physiol, 307, G66, 10.1152/ajpgi.00335.2013 · DOI
  22. Chaurasia, 2019, Targeting a ceramide double bond improves insulin resistance and hepatic steatosis, Science, 365, 386, 10.1126/science.aav3722 · DOI · Paper page
  23. Rodriguez-Cuenca, 2015, Dihydroceramide desaturase 1, the gatekeeper of ceramide induced lipotoxicity, Biochim Biophys Acta Mol Cell Biol Lipids, 1851, 40, 10.1016/j.bbalip.2014.09.021 · DOI
  24. Banini, 2021, Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis, Hepatology, 73, 1290, 10.1002/hep.31609 · DOI
  25. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  26. Abecasis, 2012, An integrated map of genetic variation from 1,092 human genomes, Nature, 491, 56, 10.1038/nature11632 · DOI · Paper page
  27. Chen, 2017, The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism, Oncotarget, 8, 74209, 10.18632/oncotarget.18474 · DOI
  28. Luukkonen, 2016, The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans, J Hepatol, 65, 1263, 10.1016/j.jhep.2016.07.045 · DOI · Paper page
  29. Shen, 2014, Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects, Nat Methods, 11, 399, 10.1038/nmeth.2857 · DOI · Paper page
  30. Quattrini, 1996, Beta 4 integrin and other Schwann cell markers in axonal neuropathy, Glia, 17, 294, 10.1002/(SICI)1098-1136(199608)17:4<294::AID-GLIA4>3.0.CO;2-# · DOI · Paper page
  31. Chirambo, 2017, The role of alkaline phosphatase in intracellular lipid accumulation in the human hepatocarcinoma cell line, HepG2, Exp Mol Pathol, 102, 224, 10.1016/j.yexmp.2017.02.007 · doi:10.1016/j.yexmp.2017.02.007
  32. Monzio Compagnoni, 2018, Mitochondrial dysfunction in fibroblasts of multiple system atrophy, Biochim Biophys Acta Mol Basis Dis, 1864, 3588, 10.1016/j.bbadis.2018.09.018 · DOI
  33. Bresolin, 1985, Fatal infantile cytochrome c oxidase deficiency: decrease of immunologically detectable enzyme in muscle, Neurology, 35, 802, 10.1212/WNL.35.6.802 · DOI
  34. Jakobi, 2020, Sorafenib treatment and modulation of the sphingolipid pathway affect proliferation and viability of hepatocellular carcinoma in vitro, Int J Mol Sci, 21, 2409, 10.3390/ijms21072409 · DOI
  35. Ezzoukhry, 2012, EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib, Int J Cancer, 131, 2961, 10.1002/ijc.27604 · DOI · Paper page

Cited by

See all 112

Metadata

Authors
Longo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., Alisi, A., Miele, L., Soardo, G., Comi, G. P., Valenti, L., Ruscica, M., Fracanzani, A. L., Gastaldelli, A., & Dongiovanni, P.
Venue
Cellular and Molecular Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2022
Volume
13
Issue
3
Pages
759-788
ISSN
2352-345X (ISSN-L)
OpenAlex
W3215865237
Cited by
112
References
15
FWCI
10.72
Type
journal article
Language
en
Open access
gold
Licence
Funders
Ministero della Salute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. https://app.cochat.ai/papers/10.1016/j.jcmgh.2021.11.007
The paper
Longo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., Alisi, A., Miele, L., Soardo, G., Comi, G. P., Valenti, L., Ruscica, M., Fracanzani, A. L., Gastaldelli, A., & Dongiovanni, P. (2022). TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. Cellular and Molecular Gastroenterology and Hepatology. https://doi.org/10.1016/j.jcmgh.2021.11.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.